Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
BiotechTV - News
00:00
Overview of verekitug and TSLP receptor approach
Rand explains varekitug's mechanism targeting the TSLP receptor and its clinical potency in type 2 inflammation.
Play episode from 00:19
Transcript
